Fred and NanoRDU, Looking at the press release
Post# of 9144
Posted On: 04/13/2016 3:28:51 PM
Fred and NanoRDU,
Looking at the press release from December 2015 when the news of the customization was released, it's clear that NanoLogix is being paid to CUSTOMIZE the N-Assay for ONE client. That probably means the client will be the only customer for THAT PARTICULAR BACTERIA detection application, with sales to follow to that CLIENT, IF the CLIENT is SATISFIED with the results. I doubt if other sales will occur for the N-Assay until after the technology results are published for public consumption in a peer-reviewed journal. I'd venture a guess that the CLIENT heard of the N-Assay through someone associated with the doctors in Texas or Chicago, or somewhere, and wanted to take it for a test drive before it becomes publicly available. I would.
"HUBBARD, OH--(Marketwired - Dec 21, 2015) - NanoLogix, Inc. (OTC PINK: NNLX), an innovator in the rapid detection, identification and determination of the antibiotic resistance and sensitivity of bacteria, is very pleased to announce that they have been contracted by one of the world's three largest global Medical Device manufacturers to customize the NanoLogix N-Assay, a unique modified ELISA diagnostic.
NanoLogix was contacted by the company in February of 2015 and the agreement was finalized in late October with a purchase order issued in late November. NanoLogix began the initial customization of the N-Assay in December, with the client billed for one-third of the contract amount. The identity of the client and further details will remain confidential as per contract restrictions until such time as NanoLogix may be permitted to comment.
The N-Assay provides extraordinarily rapid, accurate, and sensitive detection and identification of any bacteria tested to date for which there exists an antibody, with the added capability of near-simultaneous determination of antibiotic sensitivity and resistance"
Looking at the press release from December 2015 when the news of the customization was released, it's clear that NanoLogix is being paid to CUSTOMIZE the N-Assay for ONE client. That probably means the client will be the only customer for THAT PARTICULAR BACTERIA detection application, with sales to follow to that CLIENT, IF the CLIENT is SATISFIED with the results. I doubt if other sales will occur for the N-Assay until after the technology results are published for public consumption in a peer-reviewed journal. I'd venture a guess that the CLIENT heard of the N-Assay through someone associated with the doctors in Texas or Chicago, or somewhere, and wanted to take it for a test drive before it becomes publicly available. I would.
"HUBBARD, OH--(Marketwired - Dec 21, 2015) - NanoLogix, Inc. (OTC PINK: NNLX), an innovator in the rapid detection, identification and determination of the antibiotic resistance and sensitivity of bacteria, is very pleased to announce that they have been contracted by one of the world's three largest global Medical Device manufacturers to customize the NanoLogix N-Assay, a unique modified ELISA diagnostic.
NanoLogix was contacted by the company in February of 2015 and the agreement was finalized in late October with a purchase order issued in late November. NanoLogix began the initial customization of the N-Assay in December, with the client billed for one-third of the contract amount. The identity of the client and further details will remain confidential as per contract restrictions until such time as NanoLogix may be permitted to comment.
The N-Assay provides extraordinarily rapid, accurate, and sensitive detection and identification of any bacteria tested to date for which there exists an antibody, with the added capability of near-simultaneous determination of antibiotic sensitivity and resistance"
(7)
(1)